

## ContextVision - Initiation of share buyback program

**The Board of Directors of ContextVision AB ("ContextVision" or "the Company") has resolved to initiate a share buyback program to be executed in accordance with the authorization granted to the Board of Directors by the Annual General Meeting of ContextVision held on 13 May 2025 ("the Authorization").**

The share buyback program will commence on 4 September 2025 and end no later than 4 March 2026. The buyback program covers purchases for a maximum consideration of NOK 10 million, or a maximum of 4,000,000 shares in accordance with the Authorization. The purpose of the program is to reduce the capital of the Company and/or meet obligations arising from the Company's long-term incentive programs (LTIP).

ContextVision has engaged DNB Carnegie, a part of DNB Bank ASA, to manage and carry out the share repurchases in the market. DNB Carnegie will make its trading decisions independently of, and uninfluenced by ContextVision. The share buyback program will be carried out in accordance with Regulation (EU) No 596/2014 (the "Market Abuse Regulation") and Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").

The Company reserves the right to make subsequent changes to the above terms for the program and will in such case make appropriate announcements in this respect.

**For further information, please contact:**

Richard Hallström, CFO

Email: [richard.hallstrom@contextvision.com](mailto:richard.hallstrom@contextvision.com)

**About ContextVision**

ContextVision is a software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.

*This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 17. The information was submitted for publication at 2025-09-03 09:00 CEST.*